AR and prostate cancer: We have shown that carbidopa as an AhR agonist attenuates pancreatic cancer growth [29] while other investigators have shown that carbidopa suppresses prostate cancer growth via AhR-mediated ubiquitination and degradation of androgen receptor [49].